Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Clinical Trials in Chicago, Illinois

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation